Medicines and IP: Balancing Innovation and Access

The House Judiciary GOP subcommittee held a hearing on June 4, 2026, titled "Medicines and IP: Balancing Innovation and Access," focusing on the complex balance between pharmaceutical patent protections and the availability of affordable generic and biosimilar drugs. The discussion centered on the impact of patent thickets, terminal disclaimers, and recent Supreme Court decisions on drug patent litigation and market entry for generics. Witnesses debated the potential effects of proposed legislation such as the ETHIC Act and the Skinny Label Act, with some arguing these bills would reduce abusive patent practices and litigation delays, thereby improving access and lowering drug costs, while others cautioned that weakening patent protections could undermine innovation and investment in new drug development. The hearing also addressed the importance of maintaining strong intellectual property rights to sustain U.S. leadership in biopharmaceutical innovation amid global competition, particularly from China. No direct contract awards or procurement decisions were discussed, but the policy deliberations have significant implications for future pharmaceutical market dynamics and innovation incentives.